Summit Therapeutics PLC is trading at $14.44 (+4.03%) today, fueled by a series of recent positive company-specific developments. - A director, Robert W. Duggan, demonstrated strong insider confidence by investing $50 million in SMMT shares on June 12, 2026. - The company also recently withdrew a $500 million follow-on equity offering on June 16, 2026, which may have alleviated potential dilution concerns for investors. - These catalysts build on positive ivonescimab clinical data presented at the ASCO 2026 meeting in late May and early June, and the stock's movements continue to be influenced by elevated short interest.